글로벌 진핵 발현 시스템 시장 규모, 점유율 및 추세 분석 보고서 – 산업 개요 및 2031년까지의 예측

진핵생물 발현 시스템 시장 분석

진핵 발현 시스템 시장은 생명공학 의 발전과 치료용 단백질에 대한 수요 증가로 인해 빠르게 확대되고 있습니다 . 단백질 수율과 기능을 개선하는 향상된 포유류 및 효모 세포주를 만드는 것은 중요한 혁신입니다. CRISPR 및 합성 생물학과 같은 기술을 통해 보다 정확한 유전자 변형이 가능해져 보다 효과적인 발현 시스템이 탄생합니다. 나아가, 개인화된 의학의 성장으로 인해 특정 응용 분야에 맞는 맞춤형 발현 시스템에 대한 필요성이 커지고 있습니다. 이러한 시스템을 더욱 혁신하기 위해 R&D에 더 많은 비용을 투자함에 따라 기업이 비용 절감과 생산 공정 간소화에 집중함에 따라 시장이 성장할 것으로 예상됩니다. 모든 것을 고려하면 진핵 발현 시스템 시장은 시장 수요와 기술 발전으로 인해 빠르게 성장하고 있습니다.

진핵생물 발현 시스템 시장 규모

글로벌 진핵 발현 시스템 시장 규모는 2023년에 7억 2,457만 달러로 평가되었으며, 2031년까지 11억 1,220만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 5.50%입니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

진핵생물 발현 시스템 시장 동향

“ 생물약학을 위한 포유류 세포주에서의 증가”

진핵 발현 시스템 시장은 포유류 세포주 사용이 눈에 띄게 급증하고 있으며, 이는 주로 치료적 생물학제와 고품질 재조합 단백질에 대한 수요 증가에 의해 주도되고 있습니다. 포유류 시스템, 특히 중국 햄스터 난소(CHO) 및 HEK293 세포는 치료적 단백질의 효능과 안전성을 보장하는 데 필수적인 우수한 번역 후 변형을 제공합니다. 이러한 기능은 생물학제의 복잡성이 계속 증가함에 따라 점점 더 중요해지고 있습니다. 또한 CRISPR/Cas9와 같은 유전자 편집 기술 의 발전으로 안정적인 세포주를 생산하는 효율성이 크게 향상되어 포유류 발현 시스템이 생물 약리학적 응용 분야에 더욱 매력적으로 다가가고 있습니다. 기업이 보다 복잡한 생물학제 개발을 향해 선회함에 따라 포유류 발현 시스템에 대한 의존도가 높아질 것으로 예상됩니다. 이러한 추세는 세포 배양 기술의 혁신을 촉진하고 관련 기술에 대한 투자를 확대하여 생명 공학 분야의 연구 개발을 위한 강력한 환경을 조성할 것으로 예상됩니다.

보고서 범위 및 진핵 발현 시스템 시장 세분화         

Eukaryotic Expression Systems Market Definition

Eukaryotic expression systems refer to cellular systems that utilize eukaryotic cells—organisms whose cells have a nucleus—to produce proteins, particularly recombinant proteins and therapeutic biologics. These systems are essential for ensuring proper post-translational modifications, which are critical for the functionality and stability of complex proteins. Common eukaryotic expression systems include yeast, insect, and mammalian cell lines, such as Chinese hamster ovary (CHO) and HEK293 cells. These systems are widely used in biotechnology and pharmaceutical industries for producing proteins that require precise folding, glycosylation, and other modifications that prokaryotic systems like bacteria cannot provide. As a result, eukaryotic expression systems play a crucial role in the development of vaccines, antibodies, and other biologics, making them invaluable in modern medicine and research.

Eukaryotic Expression Systems Market Dynamics

Drivers

• Growth of the E. coli-Based Protein Production

The market is expanding due to the large-scale production of proteins using E. coli bacteria, the most commonly utilized artificial expression host. Its popularity stems from a well-characterized genomic and physiological sequencing system, which simplifies the cloning procedure and enhances the efficiency of recombinant protein production. For instance, E. coli can produce proteins at a rate of several grams per liter, making it cost-effective for industrial applications. Moreover, the ability to engineer promoter regions in E. coli improves transcription efficiency, increasing protein yield. This efficiency is particularly crucial in the pharmaceutical and biotechnology industries, where rapid production of therapeutics is essential. Consequently, these factors are projected to significantly boost market growth in the coming years.

• Increasing Application of Stem Cells

The need for complex proteins is growing due to advancements in stem cell research and tissue engineering, which increases the dependence on eukaryotic expression systems. For instance, the production of induced pluripotent stem cells (iPSCs) requires specialized proteins for growth and differentiation. Therefore, eukaryotic systems such as CHO and HEK293 cells are required to produce high-quality, biologically relevant proteins. For the creation of organs and tissues intended for transplantation and regenerative medicine, these proteins are necessary. In addition, the market for tissue engineering is expanding quickly as a result of the growing need for growth factors and scaffolds.

Opportunities

• Optimizing Protein Production with Synthetic Biology

The integration of synthetic biology with eukaryotic expression systems presents a significant market opportunity by enabling the engineering of new cell lines that enhance the productivity of complex protein production. By precisely manipulating genetic elements, researchers can develop cell lines optimized for specific production goals. For example, utilizing synthetic promoters and ribosome-binding sites allows for fine-tuning gene expression in CHO or HEK293 cells, ultimately increasing yields of therapeutic proteins. In addition, the incorporation of synthetic pathways can improve glycosylation patterns, enhancing the stability and functionality of these proteins. This innovative approach not only accelerates the development of biopharmaceuticals but also reduces production costs, making it a crucial advancement in the field. As biopharmaceutical companies increasingly adopt these methodologies, the market is expected to expand, fostering further innovations in protein production and therapeutic development.

•  Eukaryotic Expression Systems in Biosimilars Production

The market for therapeutic biologics that closely resemble approved products, or biosimilars, is expanding, and this presents eukaryotic expression systems with considerable opportunities to produce these less expensive alternatives. The market for biosimilars is expected to expand quickly as original biologics lose their patent protection, since patients and healthcare providers are beginning to recognize them more and more for their affordability. For the production of biosimilars, eukaryotic systems—in particular, CHO and HEK293 cell lines—are essential because they enable the post-translational modifications required to guarantee safety and efficacy. Manufacturers can now meet the growing demand for biosimilars thanks to recent developments in bioprocessing technologies, which enable faster development cycles and higher yields. This trend enhances accessibility to essential therapies and drives innovation within the biopharmaceutical industry.

Restraints/Challenges

• High Production Cost

Smaller biotech companies, eukaryotic expression systems—particularly mammalian cell lines—can be unaffordably costly to maintain and run. The financial load is increased by the expenses related to sophisticated culture media, bioreactor systems, and strict environmental regulations. For instance, maintaining ideal growth conditions for HEK293 or CHO cells necessitates highly qualified staff and sophisticated infrastructure, which raises operating costs. Moreover, it can take months or even years to develop stable cell lines, which raises costs even more. This financial barrier may impede innovation in biopharmaceutical development by preventing smaller companies from accessing state-of-the-art expression technologies. Because of this, many startups might find it difficult to compete with larger companies that can afford to purchase these advanced systems.

• Technological Limitations

Certain complex proteins are difficult for current eukaryotic expression systems to produce, particularly those that need particular post-translational modifications (PTMs) to function properly. For instance, complex glycosylation patterns in proteins—like therapeutic antibodies—may prevent them from achieving the required structural integrity in conventional mammalian systems. Glycosylation variations between animal and human cell lines can lead to increased immunogenicity and changed efficacy, which reduces the therapeutic potential of these proteins. Furthermore, it might not be possible to produce enough proteins that need special phosphorylation or lipidation modifications, which would restrict their application in targeted therapies. The challenge of accurately replicating the entire range of human PTMs limits the suitability of eukaryotic systems for the creation of specific sophisticated biologics, thereby affecting their overall commercial viability.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Eukaryotic Expression Systems Market Scope

The market is segmented on the basis of type, host type, and application. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• MEL
• COS
• CHO
• Insect cells
• Reagents
• Expression Vectors
• Competent Cells

Host Type

• S. cerevisiae
• Filamentous Fungi
• Leishmania
• Baculovirus-Infected Cells

Application

• Bacterial Expression System
• Yeast Expression System
• Insect Expression System
• Mammalian Expression System

Eukaryotic Expression Systems Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, type, host type, and application as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the eukaryotic expression systems market, driven by continuous advancements in genome sequencing and significant innovations in proteomics, particularly in the United States and Canada. This region benefits from a robust research infrastructure, enabling cutting-edge developments in biotechnology and pharmaceutical applications. In addition, strong investments in research and development by both public and private sectors further enhance the capabilities of eukaryotic expression systems, positioning North America as a leader in the global market.

The Asia-Pacific region is set to become a leading force in the eukaryotic expression systems market from 2022 to 2029, driven by a surge in research studies conducted by market participants. Increased investment in research and development activities is further propelling this growth, as companies seek to innovate and enhance their capabilities. In addition, the rising awareness of biotechnology and the growing demand for therapeutic biologics in this region are expected to contribute significantly to market expansion during the forecast period.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Eukaryotic Expression Systems Market Share

시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 애플리케이션 우세입니다. 위에 제공된 데이터 포인트는 시장과 관련된 회사의 초점에만 관련이 있습니다.

시장에서 운영되는 진핵 발현 시스템 시장 리더는 다음과 같습니다.

• Agilent Technologies, Inc. (미국)
• 머크 KGaA(독일)
• Bio-Rad Laboratories, Inc. (미국)
• QIAGEN(독일)
• 프로메가 코퍼레이션(미국)
• Thermo Fischer Scientific, Inc. (미국)
• 다카라바이오 주식회사(일본)
• 젠스크립트(미국)
• 뉴잉글랜드 바이오랩스(미국)
• Oxford Expression Technologies Ltd(영국)
• LifeSensors Inc. (미국)
• 론자(스위스)
• proteogenixx (프랑스)
• 시그네이처 디스커버리(영국)
• Sino Biological Inc. (중국)
• ARTES Biotechnology GmbH (독일)

진핵 발현 시스템 시장의 최신 개발

• 2022년 10월, 이 회사는 텍사스 휴스턴과 네덜란드 헬렌에 있는 시설에서 세포 및 유전자 치료(CGT) 공정 및 분석 개발 실험실을 확장할 계획을 발표했습니다. 이 전략적 확장은 혁신적인 CGT 솔루션을 개발하는 역량을 강화하여 고급 치료 옵션에 대한 증가하는 수요에 대응하는 것을 목표로 합니다. 이 회사는 최첨단 실험실에 투자함으로써 연구 개발을 가속화하고 궁극적으로 빠르게 진화하는 생명공학 환경에서 치료 제품의 효율성과 효과를 개선하고자 합니다.

SKU-56080